Review Article
Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
Table 2
FDA-approved PD-1/L1/2 inhibitors for various malignancies.
| | Target | Agent | Class | Cancer |
| | PD-1 | Pembrolizumab (MK-3475, Keytruda) | Humanized IgG4k | Melanoma | | Breast cancer | | Non-small-cell lung cancer | | Small-cell lung cancer | | Head and neck squamous cell cancer | | Hodgkin lymphoma | | Gastric/gastroesophageal junction (GEJ) adenocarcinoma | | Cervical cancer | | Endometrial carcinoma | | Primary mediastinal large B cell lymphoma | | Hepatocellular carcinoma | | Merkel cell carcinoma | | Renal cell cancer | | Urothelial cancer | | Nivolumab (MDX1106, Opdivo) | Humanized IgG4 | Melanoma | | Non-small-cell lung cancer | | Small-cell lung cancer | | Renal cell cancer | | Hodgkin lymphoma | | Head and neck squamous cell cancer | | Urothelial cancer | | Colorectal cancer | | Hepatocellular carcinoma | | Metastatic esophageal squamous cell carcinoma (ESCC) | | Cemiplimab (Libtayo) | Monoclonal antibody/antibody-drug conjugate | Cutaneous squamous cell carcinoma |
| | PD-L1 | Atezolizumab (MPDL-3280A, Tecentriq) | Humanized IgG1k | Urothelial carcinoma | | Non-small-cell lung cancer | | Small-cell lung cancer | | Hepatocellular carcinoma | | Breast cancer | | Durvalumab (MEDI4736, Imfinzi) | Human IgG1k | Urothelial carcinoma | | Non-small-cell lung cancer | | Small-cell lung cancer | | Avelumab (MSB0010718C, Bavencio) | Human IgG1 | Merkel cell carcinoma | | Urothelial carcinoma | | Renal cell cancer |
|
|
Data are included as of June 5, 2020. Ig: immunoglobulin; PD-1: programmed cell death protein 1; PD-L1: programmed death ligand 1.
|
